ArticleJournal of molecular histology2025
Knockout of the Staphylococcus aureus virulence gene sdrC promotes Myh7 expression to inhibit the progression of osteomyelitis.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The incidence of osteomyelitis has been increasing annually, but the specific molecular pathogenesis of Staphylococcus aureus-induced osteomyelitis is unclear. The SdrC protein facilitates Staphylococcus aureus adhesion and colonization, thereby promoting subsequent biofilm accumulation and contributing to the progression of osteomyelitis. The role of SdrC, an important protein in S. aureus, in the progression of S. aureus-induced osteomyelitis requires further elucidation. Thus, we aimed to determine whether targeting SdrC is a novel strategy for treating S. aureus-induced osteomyelitis. The sdrC sequence of S. aureus was knocked out, and rat models with wild-type and sdrC knockout (KO) S. aureus-induced osteomyelitis were established. Enzyme-linked immunosorbent assays (ELISAs) were used to identify differences in the levels of the inflammatory factors IL-6 and TNF-α, and qPCR and Western blotting were used to identify changes in the levels of osteogenic indicators, such as ALP, OST and Runx2; these experiments analyzed the role of SdrC in the progression of S. aureus-induced osteomyelitis. Transcriptomic sequencing was used to explore the mechanism by which SdrC promotes the development of S. aureus-induced osteomyelitis at the molecular level. After the SdrC protein of S. aureus was knocked out, biofilm formation significantly decreased. Compared with the control group, The sdrC-KO osteomyelitis group showed milder bone tissue inflammation compared to the control group, and the expression of the inflammatory factors IL-6 and TNF-α decreased significantly (p < 0.05), whereas the expression of the osteogenic indicators ALP, OST, and Runx2 increased significantly, as shown by qPCR and Western blotting (p < 0.05). Alkaline phosphatase and alizarin red staining showed that knocking out SdrC increased ossification in rats and improved their prognosis. Transcriptomic sequencing revealed that Myh7 was significantly overexpressed in the sdrC-KO rats with osteomyelitis (p < 0.05). Knocking out Myh7 significantly reduced the mRNA and protein levels of osteogenic markers Runx2, ALP, Osterix (OSX), and osteocalcin (p < 0.05), suggesting that Myh7 inhibits the function of the S. aureus SdrC protein. The SdrC protein in S. aureus promotes the malignant progression of osteomyelitis and exacerbates the development of osteomyelitis by promoting S. aureus biofilms. Moreover, Myh7 hinders the ability of SdrC to promote biofilm formation, reducing the progression of osteomyelitis; these findings suggest that targeting SdrC or enhancing Myh7 expression could serve as a novel therapeutic strategyjbr osteomyelitis treatment.
Indexed as
Identifiers
40471432What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.